Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 5, 2008, Pages 865-873

  Saleem, A ^a   Aboagye, E O ^b   Matthews, J C ^c   Price, P M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5 Fluorouracil; Microdosing; N 2 (dimethylamino) ethyl acridine 4 carboxamide; PET; Pharmacokinetics; Tracer studies

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 11; CYTOTOXIC AGENT; FLUORINE 18; FLUOROURACIL; FLUOROURACIL F 18; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE C 11; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTERIAL BLOOD; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SCREENING; HUMAN; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY;

EID: 39749193560     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0552-2     Document Type: Article

References (29)

1. 1. RG Stoller 1977 Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity N Engl J Med 297 12 630 634 302412 1:STN:280:DyaE2s3lsVyrsQ%3D%3D 10.1056/NEJM197709222971203 Stoller RG et al (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 297(12):630–634
2. 2. AH Calvert 1989 Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 11 1748 1756 2681557 1:STN:280:DyaK3c%2FjvFCmug%3D%3D Calvert AH et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748–1756
3. 3. W Wolf V Waluch CA Presant 1998 Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies NMR Biomed 11 7 380 387 9859944 10.1002/(SICI)1099-1492(1998110)11:7<380::AID-NBM517>3.0.CO;2-Q 1:CAS:528:DyaK1MXmtVSl Wolf W, Waluch V, Presant CA (1998) Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed 11(7):380–387
4. 4. A Saleem EO Aboagye PM Price 2000 In vivo monitoring of drugs using radiotracer techniques Adv Drug Deliv Rev 41 1 21 39 10699303 10.1016/S0169-409X(99)00054-X 1:CAS:528:DC%2BD3cXhsVWqs7Y%3D Saleem A, Aboagye EO, Price PM (2000) In vivo monitoring of drugs using radiotracer techniques. Adv Drug Deliv Rev 41(1):21–39
5. 5. M Bergstrom A Grahnen B Langstrom 2003 Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development Eur J Clin Pharmacol 59 5, 6 357 366 12937873 10.1007/s00228-003-0643-x Bergstrom M, Grahnen A, Langstrom B (2003) Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 59(5, 6):357–366
6. 6. A Saleem 2001 Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography J Clin Oncol 19 5 1421 1429 11230487 1:CAS:528:DC%2BD3MXit1ertL0%3D Saleem A et al (2001) Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol 19(5):1421–1429
7. 7. GD Brown 1999 Radiolabelling of anticancer drugs with short-lived positron emitters for PET studies University of London London 256 Brown GD (1999) Radiolabelling of anticancer drugs with short-lived positron emitters for PET studies. University of London, London, p 256
8. 8. GD Brown 1993 A practical synthesis of 5-[18F]Fluorouracil using HPLC and a study of its metabolic profile in rats J Label Compd Radiopharm 32 521 522 Brown GD et al (1993) A practical synthesis of 5-[18F]Fluorouracil using HPLC and a study of its metabolic profile in rats. J Label Compd Radiopharm 32:521–522
9. 9. GD Brown 1994 Carbon-11 labelling of the antitumour agent, [N-11 C-methyl] NSC 601316 for pre-clinical evaluation in man by PET J Label Compd Radiopharm 35 558 Brown GD et al (1994) Carbon-11 labelling of the antitumour agent, [N-11 C-methyl] NSC 601316 for pre-clinical evaluation in man by PET. J Label Compd Radiopharm 35:558
10. 10. RJ Harte 1999 Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa J Clin Oncol 17 5 1580 1588 10334547 1:CAS:528:DyaK1MXjsF2ms7k%3D Harte RJ et al (1999) Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. J Clin Oncol 17(5):1580–1588
11. 11. A Saleem 2000 Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action Lancet 355 9221 2125 2131 10902627 10.1016/S0140-6736(00)02380-1 1:CAS:528:DC%2BD3cXkvVWjtrk%3D Saleem A et al (2000) Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 355(9221):2125–2131
12. 12. DZ D’Argenio A Schumitzky 1997 A program package for simulation and parameter estimation in pharmacokinetic systems Comput Programs Biomed 9 2 115 134 10.1016/0010-468X(79)90025-4 D’Argenio DZ, Schumitzky A (1997) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9(2):115–134
13. 13. S Osman 1997 Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials Cancer Res 57 11 2172 2180 9187117 1:CAS:528:DyaK2sXjslGlt7c%3D Osman S et al (1997) Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials. Cancer Res 57(11):2172–2180
14. 14. C Heidelberger 1957 Fluorinated pyrimidines, a new class of tumour-inhibitory compounds Nature 179 4561 663 666 13418758 10.1038/179663a0 1:CAS:528:DyaG1cXislyn Heidelberger C et al (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179(4561):663–666
15. 15. PJ Finan 1987 The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer Eur J Surg Oncol 13 4 349 353 2957234 1:STN:280:DyaL2szgsVyltQ%3D%3D Finan PJ et al (1987) The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer. Eur J Surg Oncol 13(4):349–353
16. 16. RJ Fraile 1980 Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion Cancer Res 40 7 2223 2228 7388790 1:STN:280:DyaL3c3it1GmsA%3D%3D Fraile RJ et al (1980) Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40(7):2223–2228
17. 17. JM Collins 1980 Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes Clin Pharmacol Ther 28 2 235 246 7398191 1:CAS:528:DyaL3cXls1Sqsr4%3D 10.1038/clpt.1980.156 Collins JM et al (1980) Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 28(2):235–246
18. 18. CJ Groeningen van 1988 Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule Cancer Res 48 23 6956 6961 3180104 van Groeningen CJ et al (1988) Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48(23):6956–6961
19. 19. GD Heggie 1987 Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile Cancer Res 47 8 2203 2206 3829006 1:STN:280:DyaL2s7lvFaqtw%3D%3D Heggie GD et al (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47(8):2203–2206
20. 20. WE MacMillan WH Wolberg PG Welling 1978 Pharmacokinetics of fluorouracil in humans Cancer Res 38 10 3479 3482 688233 1:STN:280:DyaE1M%2FgtFKitA%3D%3D MacMillan WE, Wolberg WH, Welling PG (1978) Pharmacokinetics of fluorouracil in humans. Cancer Res 38(10):3479–3482
21. 21. DV Spicer 1988 Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics Cancer Res 48 2 459 461 3335014 1:STN:280:DyaL1c%2FotVSlsw%3D%3D Spicer DV et al (1988) Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res 48(2):459–461
22. 22. C Erlichman S Fine T Elhakim 1986 Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol Cancer Treat Rep 70 7 903 904 3719584 1:STN:280:DyaL283ksVOrtA%3D%3D Erlichman C, Fine S, Elhakim T (1986) Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treat Rep 70(7):903–904
23. 23. RA Fleming 1992 Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients Cancer Res 52 10 2899 2902 1581906 1:CAS:528:DyaK38XktVShtL8%3D Fleming RA et al (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52(10):2899–2902
24. 24. A Thyss 1986 Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer Cancer Chemother Pharmacol 16 1 64 66 3940221 10.1007/BF00255288 1:STN:280:DyaL28%2Fltlyguw%3D%3D Thyss A et al (1986) Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16(1):64–66
25. 25. P Kestell 1999 Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial Cancer Chemother Pharmacol 44 1 45 50 10367748 10.1007/s002800050943 1:CAS:528:DyaK1MXjtlWkurk%3D Kestell P et al (1999) Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial. Cancer Chemother Pharmacol 44(1):45–50
26. 26. DJ Propper 2003 Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000 J Clin Oncol 21 2 203 210 12525511 10.1200/JCO.2003.02.008 1:CAS:528:DC%2BD2cXpsVWqsrk%3D Propper DJ et al (2003) Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol 21(2):203–210
27. 27. CJ Twelves 1999 Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II Br J Cancer 80 11 1786 1791 10468297 10.1038/sj.bjc.6690598 1:CAS:528:DyaK1MXlvFGntb8%3D Twelves CJ et al (1999) Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee. Br J Cancer 80(11):1786–1791
28. 28. EO Aboagye 2001 Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer Cancer Res 61 13 4937 4941 11431319 1:CAS:528:DC%2BD3MXltVeqtLg%3D Aboagye EO et al (2001) Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 61(13):4937–4941
29. 29. SR Meikle 1998 Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study Cancer Chemother Pharmacol 42 3 183 193 9685053 10.1007/s002800050804 1:CAS:528:DyaK1cXks1yiur0%3D Meikle SR et al (1998) Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother Pharmacol 42(3):183–193